Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Anas Younes, MD, Laurie H Sehn, MDMPH, Peter Johnson, MD, Pier Luigi Zinzani, MD, Xiaonan Hong, MD, Jun Zhu, Olga Samoilova, MD, Cheolwon Suh, Itaru Matsumura, MD, Andres Lopez-Hernandez, MD, Ulrich Dührsen, Prof, MD PhD, Catherine Thieblemont, MD, Jodi Carey, BSN, RN, Grace Liu, PhD, S. Martin Shreeve, MD PhD, Steven Sun, PhD, Jessica Vermeulen, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 784.

https://doi.org/10.1182/blood-2018-99-112988

Published: 2018

Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Blood (2018) 132 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2018-99-110792

Published: 2018

Journal Articles

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Eva Gonzalez-Barca, MD PhD, Maria Queralt Salas Gay, MD, Francisco Javier Capote Huelva, Jose Gomez Codina, Carlos Panizo, MD PhD, Antonio Salar, MD PhD, Eva Domingo Domenech, MD, Alicia Bailen, Josep-Maria Ribera, MD, Andres Lopez, Javier Briones, MD, Andres Muñoz, Maite Encuentra, Alberto Fernandez de Sevilla, MD PhD

Blood (2017) 130 (Supplement 1): 1545.

https://doi.org/10.1182/blood.V130.Suppl_1.1545.1545

Published: 2017

Journal Articles

NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis

Juan Miguel Bergua Burgues, Luis Lopez-Gomez, MD PhD, Fatima Ibañez, MD, Sara Suarez-Varela, MD, Julio Prieto-Fernandez, Fernando Carnicero, Ignacio Casas, MD, Maria Luisa Martín-Mateos, Carmen Cabrera, María José Arcos-Carmona, MD, M Helena Bañas, MD, Nuria Bermejo, MD, Miguel A. Sanz, MD PhD, Sara Bobillo-Varela, MD, Andres Lopez

Blood (2016) 128 (22): 5401.

https://doi.org/10.1182/blood.V128.22.5401.5401

Published: 2016

Journal Articles

Ocular Adnexal Marginal Zone Lymphomas (OAMZL): Lack of Evidence for Chlamydia Psittaci (C. Psittaci) Infection in a Clinicopathologic Study from a Single Institution

Brayan Marcel Merchán, MD, Anny Jaramillo, MD, Teresa Tortola, Pau Abrisqueta, MD, Josep Castellvi, MD, Ramón Medel, MD, Katia Flores, MD, Javier Hernandez, MD, Mercedes Gironella, MD, Andres Lopez-Hernandez, MD PhD, Francesc Bosch, MD PhD

Blood (2014) 124 (21): 4467.

https://doi.org/10.1182/blood.V124.21.4467.4467

Published: 2014

Journal Articles

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Pilar Giraldo, MD PhD, Andres Lopez, MD PhD, Eduardo Rios, MD, Felix Carbonell, MD PhD, Javier Lopez, Angel Ramírez, MD, Alicia Rodriguez, MD, Marta Gomez, MD, Ricardo Garcia, MD, Patricia Baltasar, MD, Maria Duran, MD, Raul Perez, MD, Maria Garcia, MD, José Antonio Márquez, Javier De la Serna, MD PhD

Blood (2014) 124 (21): 5666.

https://doi.org/10.1182/blood.V124.21.5666.5666

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Blood (2014) 124 (21): 3980.

https://doi.org/10.1182/blood.V124.21.3980.3980

Published: 2014

Journal Articles

Prospective, Observational Study To Assess The Safety Of Rituximab In Combination With Chemotherapy In Patients With Previously-Untreated Or Relapsed Or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Preliminary Results

Andres Lopez, Eduardo Rios, MD, Javier De la Serna, MD, PhD, Felix Carbobnell, MD, Cristina Garcia Bernaldez, Isabel Gonzalez-Grande, Pilar Giraldo, MD PhD

Blood (2013) 122 (21): 5310.

https://doi.org/10.1182/blood.V122.21.5310.5310

Published: 2013

Journal Articles

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Blood (2013) 122 (21): 369.

https://doi.org/10.1182/blood.V122.21.369.369

Published: 2013

Journal Articles

Gemcitabine and Oxaliplatinum (GemOx): An Effective Regimen in Patients with Refractory and Relapsing Hodgkin Lymphoma

Antonio Gutierrez, MD, PhD, Jose Rodriguez, Andres Lopez, Jordi Martinez-serra, Jorge Gines, María Pilar Paredes, Florencia Garcia, Javier Vercher, Josep Balanzat, Raquel Del campo, Pilar Galan, Miguel Morey, Joan Bargay, Juan Besalduch, MD, PhD

Blood (2012) 120 (21): 4845.

https://doi.org/10.1182/blood.V120.21.4845.4845

Published: 2012

Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma

Mercedes Gironella, MD, Andres Lopez, Brayan Merchan, Pau Abrisqueta, MD, Anny Jaramillo, MD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 1627.

https://doi.org/10.1182/blood.V120.21.1627.1627

Published: 2012

Journal Articles

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur, MD, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez

Blood (2011) 118 (21): 593.

https://doi.org/10.1182/blood.V118.21.593.593

Published: 2011

Journal Articles

miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy

Blood (2011) 118 (4): 1034–1040.

https://doi.org/10.1182/blood-2010-11-321554

Published: 2011

Includes: Supplemental data

Journal Articles

A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

Blood (2010) 116 (8): e12–e17.

https://doi.org/10.1182/blood-2010-02-270009

Published: 2010

Journal Articles

Rituximab-EPOCH, an Efective Front-Line Therapy for Mantle Cell Lymphoma.

Andres Palacios, MD, Andres Lopez, MD, Antonio Salar, MD, Marta Cervera, MD, Merche Gironella, MD

Blood (2007) 110 (11): 4490.

https://doi.org/10.1182/blood.V110.11.4490.4490

Published: 2007

Journal Articles

Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.

Andres Palacios, Mayda Navarrete, Laura Gallur, Javier Zuazu, Cristina Barrenetxea, Eva Sanchez, Andres Lopez

Blood (2006) 108 (11): 4707.

https://doi.org/10.1182/blood.V108.11.4707.4707

Published: 2006

Journal Articles

Serum Levels of Soluble Interleukin 10 (IL-10) in Patients with Hodgkin’s Lymphoma: Predictive Value in Advanced Stage.

Mayda Navarrete, MD, Andres Palacios, MD, Maria J. Cruz, BD, Adoracion Blanco, BD, Isabel Caragol, MD,PhD, Andres Lopez, MD, PhD

Blood (2006) 108 (11): 4590.

https://doi.org/10.1182/blood.V108.11.4590.4590

Published: 2006

Journal Articles

Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.

Blood (2005) 106 (11): 774.

https://doi.org/10.1182/blood.V106.11.774.774

Published: 2005

Journal Articles

Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.

Andres Lopez, Alberto Fernandez de Sevilla, Sylvie Castaigne, Richard Greil, Jorge Sierra, Jordi Sanchez, Valerie Easton, Pamela Bacon

Blood (2004) 104 (11): 3311.

https://doi.org/10.1182/blood.V104.11.3311.3311

Published: 2004

NARROW

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis

Ocular Adnexal Marginal Zone Lymphomas (OAMZL): Lack of Evidence for Chlamydia Psittaci (C. Psittaci) Infection in a Clinicopathologic Study from a Single Institution

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Prospective, Observational Study To Assess The Safety Of Rituximab In Combination With Chemotherapy In Patients With Previously-Untreated Or Relapsed Or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Preliminary Results

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Gemcitabine and Oxaliplatinum (GemOx): An Effective Regimen in Patients with Refractory and Relapsing Hodgkin Lymphoma

Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy

A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

Rituximab-EPOCH, an Efective Front-Line Therapy for Mantle Cell Lymphoma.

Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.

Serum Levels of Soluble Interleukin 10 (IL-10) in Patients with Hodgkin’s Lymphoma: Predictive Value in Advanced Stage.

Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.

Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only